Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Sweden
/
Pharmaceuticals & Biotech
/
Cinclus Pharma Holding
CINPHA
Cinclus Pharma Holding
Clinical And Regulatory Obstacles Will Challenge Gastroenterology Prospects Despite Optimism
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
SEK 50.00
68.6% undervalued
intrinsic discount
24 Aug
SEK 15.70
1Y
-49.0%
7D
-4.6%
Loading
1Y
-49.0%
7D
-4.6%
Author's Valuation
SEK 50.0
68.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
SEK 50.0
68.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-249m
325m
2019
2021
2023
2025
2027
2028
Revenue SEK 325.2m
Earnings SEK 72.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
40.90%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
SEK 72.10m
Earnings '28
x
36.84x
PE Ratio '28
=
SEK 2.66b
Market Cap '28
SEK 2.66b
Market Cap '28
/
46.54m
No. shares '28
=
SEK 57.08
Share Price '28
SEK 57.08
Share Price '28
Discounted to 2025 @ 4.92% p.a.
=
SEK 49.42
Fair Value '25
